All In Biotech

Drug Trial Radar · NCT07279766

Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 41,060 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

41,060

Actual

Start

Dec 11, 2025

Primary completion

Aug 26, 2026

Study completion Sep 5, 2026

Sponsor

Lead sponsor
Tor Biering-SørensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ModernaTX, Inc.
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.

Conditions

  • COVID-19

Interventions

  • mRNA-1273 (Moderna COVID-19 vaccine)Biological

    For this arm, the current variant formulation of Spikevax (mRNA-1273) vaccine will be used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Medically attended COVID-19Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

    Hellerup, Denmark

  • Danske Lægers Vaccinations Service

    Søborg, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.